<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="32950">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02677701</url>
  </required_header>
  <id_info>
    <org_study_id>TEACH-IP-15</org_study_id>
    <secondary_id>1R01HL124053-01A1</secondary_id>
    <secondary_id>NICHOL15A0</secondary_id>
    <nct_id>NCT02677701</nct_id>
  </id_info>
  <brief_title>Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With CF</brief_title>
  <acronym>TEACH</acronym>
  <official_title>TEACH Trial: Testing the Effect of Adding CHronic Azithromycin to Inhaled Tobramycin. A Randomized, Placebo-controlled, Double-blinded Trial of Azithromycin 500mg Thrice Weekly in Combination With Inhaled Tobramycin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cystic Fibrosis Foundation Therapeutics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CF Therapeutics Development Network Coordinating Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to examine the effect of combining chronic oral azithromycin with inhaled
      tobramycin in adolescent and adult subjects with cystic fibrosis who are chronically
      infected with P. aeruginosa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, randomized, double-blinded, placebo-controlled trial of
      azithromycin 500mg taken orally thrice weekly vs. placebo in subjects with cystic fibrosis
      and chronic airway infection with P. aeruginosa who are utilizing chronic inhaled tobramycin
      therapy. It will include approximately 120 subjects able to complete a primary 6-week study
      phase. Subjects will be at least 12 years old with a baseline FEV1 between 25-100%
      predicted. Subjects will continue to use clinically prescribed inhaled tobramycin cycled
      on/off every 4 weeks. They will be provided over-encapsulated azithromycin 500mg tablets or
      placebo during the primary study phase. An optional extension phase will be offered to all
      subjects completing the primary 6-week study. This 8-week extension phase will include an
      initial 4 weeks without use of inhaled tobramycin or other inhaled antibiotics, followed by
      a 4-week period with inhaled tobramycin use. All subjects participating in the extension
      phase of the study will be provided azithromycin 500mg tablets to be taken thrice weekly for
      the entire 8-week period.

      This study will investigate how use of chronic oral azithromycin affects some of the
      previously demonstrated benefits to health when using inhaled tobramycin. The primary
      measurements will focus on lung function. Additional measurements will focus on
      disease-related quality of life as reported by subjects in the trial. Exploratory outcomes,
      including measurements of safety, are also planned.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>relative change in lung function</measure>
    <time_frame>baseline (week 0) to week 6 (6 week period)</time_frame>
    <description>Relative change in FEV1 volume (L) from enrollment at week 0 to the end of the 4-week period with inhaled tobramycin at week 6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>relative change in lung function</measure>
    <time_frame>week 2 to week 6 (4 week period)</time_frame>
    <description>Relative change in FEV1 (L) from the beginning of the 4-week period with inhaled tobramycin at week 2 to the end of the 4-week period with inhaled tobramycin at week 6</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>azithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>azithromycin 500mg tablet over-encapsulated to match placebo in appearance, taken by mouth thrice weekly for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>encapsulated placebo taken by mouth thrice weekly for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azithromycin</intervention_name>
    <description>500mg tablet over-encapsulated to match placebo</description>
    <arm_group_label>azithromycin</arm_group_label>
    <other_name>Zithromax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo (for azithromycin)</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhaled tobramycin</intervention_name>
    <description>clinically prescribed inhaled tobramycin used by subjects participating in the study</description>
    <arm_group_label>azithromycin</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  12 years old or older

          -  documented diagnosis of cystic fibrosis

          -  written informed consent (and assent when applicable)

          -  at least two respiratory cultures growing P. aeruginosa within the last 12 months

          -  FEV1% predicted between 25-100%

          -  use of at least two cycles of inhaled tobramycin within the last 24 weeks

          -  most recent liver function test results less than 4 times the upper limit of normal,
             obtained within the last 12 months

          -  prior or current use of azithromycin for at least four consecutive weeks

          -  stable clinical status and therapeutic regimen

        Exclusion Criteria:

          -  weight &lt;40 kg

          -  positive pregnancy test, lactating, or unwillingness to practice a pre-defined form
             of contraception, which includes abstinence

          -  inability to perform reproducible spirometry

          -  inability or unwillingness to cycle off of inhaled tobramycin for one 4-week period
             and without use of any additional inhaled antibiotics

          -  respiratory culture with Burkholderia cepacia complex species within 24 months or
             with nontuberculous mycobacteria within 18 months of screening

          -  use of intravenous or oral anti-pseudomonal antibiotics within 4 weeks of screening

          -  use of investigational therapy within 4 weeks of screening

          -  use of systemic corticosteroids equivalent to a daily dose more than 10mg of
             prednisone

          -  use of nelfinavir, warfarin, haloperidol, or methadone (concern of drug interaction
             with azithromycin)

          -  initiation of CFTR modulator therapy within 30 days

          -  ECG abnormality at screening requiring prompt further medical attention, or QTc
             interval &gt;480 msec for males and &gt;486 msec for females

          -  any other condition that, in the opinion of the site investigator, would compromise
             the safety of the subject or quality of the data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David P Nichols, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David P Nichols, MD</last_name>
    <phone>303-398-1876</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Mead</last_name>
    <phone>206-884-7531</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy DeBlaise-Kasai</last_name>
      <email>akasai@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Keens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Connie St. Clair</last_name>
      <email>stclairc@njhealth.org</email>
    </contact>
    <investigator>
      <last_name>Jerry Nick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shands Hospital</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wanda Nichols</last_name>
      <email>nichowj@medicine.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Jorge Lascano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Hosptial</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Omar (Hector) Oquendo</last_name>
      <email>omar.oquendoflores@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Floyd Livingston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandria Clarke</last_name>
      <email>alexandria.clarke@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Manu Jain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Longtine</last_name>
      <email>karen.longtine@umassmed.edu</email>
    </contact>
    <investigator>
      <last_name>Evan Bailey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DeVos Children's Hospital at Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Gile</last_name>
      <email>cynthia.gile@spectrumhealth.org</email>
    </contact>
    <investigator>
      <last_name>Susan Millard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Masonic Children's Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brooke Noren</last_name>
      <email>boer0039@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Theresa (Terri) Laguna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Candy Schmoll</last_name>
      <email>cschmoll@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Philip Black, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morgan Stanley Children's Hospital of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hossein Sadeghi</last_name>
      <email>hs762@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Hossein Sadeghi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Weaver</last_name>
      <email>david.weaver@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>James Chmiel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Sciences University Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brendan Klein</last_name>
      <email>kleinb@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Kelvin MacDonald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Hartigan</last_name>
      <email>elizabeth.hartigan@chp.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Spahr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98145</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon McNamara, RN</last_name>
      <phone>206-987-1427</phone>
      <email>sharon.mcnamara@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Ron Gibson, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Moira Aitken, MD</last_name>
      <email>moira@u.washington.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Kump</last_name>
      <email>tkump@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Diana Quintero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 1, 2017</lastchanged_date>
  <firstreceived_date>January 29, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seattle Children's Hospital</investigator_affiliation>
    <investigator_full_name>David Nichols, MD</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tobramycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
